REFERENCES:
1. Castana O, Rempelos G, Anagiotos G, Apostolopoulou C, Dimitrouli A, Alexakis D. Stevens-johnson syndrome: a case report. Ann Burns Fire Disasters. 2009;22(3):147-151.
2. La Grenade L, Lee L, Weaver J, Bonnel R, Karwoski C, Governale L, Brinker A. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28(10):917–924.
3. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44.
4.Halevy, S., Ghislain, P. D., Mockenhaupt, M., Fagot, J. P., Bavinck, J. N. B., Sidoroff, A., & EuroSCAR Study Group. (2008). Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. Journal of the American Academy of Dermatology58 (1), 25-32.
5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Daunorubicin. [Updated 2017 Dec 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548259/
6. Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs . 2014;25(2):225-234
7. Saleem T, Kasi A. Daunorubicin. [Updated 2020 Sep 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559073/
8. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault AJ Invest Dermatol. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.2008 Jan; 128(1):35-44.
9. Roujeau, J. C. et al.  Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med.  333 , 1600–1607. https://doi.org/10.1056/NEJM199512143332404 (1995).